Monte Rosa Therapeutics, Inc. SEC filings GLUE
Monte Rosa Therapeutics, Inc. has 401 filings in SEC EDGAR's recent list, going back to Sep 29, 2020. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| UPLOAD | Letter from the SEC | Aug 21, 2025 | — |
| CORRESP | Letter to the SEC | Jul 22, 2025 | — |
| UPLOAD | Letter from the SEC | Jul 15, 2025 | — |
| EFFECT | Filing | Mar 31, 2025 | — |
| CORRESP | Letter to the SEC | Mar 27, 2025 | — |
| UPLOAD | Letter from the SEC | Mar 26, 2025 | — |
| EFFECT | Filing | Jul 13, 2022 | — |
| CORRESP | Letter to the SEC | Jul 11, 2022 | — |
| UPLOAD | Letter from the SEC | Jul 8, 2022 | — |
| SEC STAFF LETTER | Filing | Jun 23, 2021 | — |
| EFFECT | Filing | Jun 23, 2021 | — |
| CERT | Filing | Jun 22, 2021 | — |
| 8-A12B | Filing | Jun 21, 2021 | — |
| CORRESP | Letter to the SEC | Jun 21, 2021 | — |
| CORRESP | Letter to the SEC | Jun 21, 2021 | — |
| CORRESP | Letter to the SEC | Jun 21, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 15, 2021 | — |
| CORRESP | Letter to the SEC | Jun 11, 2021 | — |
| CORRESP | Letter to the SEC | Jun 9, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 7, 2021 | — |
| SEC STAFF LETTER | Filing | May 25, 2021 | — |
| DRSLTR | Filing | May 21, 2021 | — |
| DRS/A | Filing | May 21, 2021 | — |
| UPLOAD | Letter from the SEC | May 17, 2021 | — |
| DRS/A | Filing | Apr 30, 2021 | — |
| DRS | Filing | Apr 19, 2021 | — |
| D | Filing | Mar 24, 2021 | — |
| D | Filing | Sep 29, 2020 | — |
Showing 28 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- GLUE (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1826457
- Former names
- Monte Rosa Therapeutics, Inc. (until Nov 5, 2026)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.